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ApoptosisThe p53 tumor suppressor gene is one of the most commonly mutated genes in human cancers and the
corresponding encoded protein induces apoptosis or cell-cycle arrest at the G1/S checkpoint in response to
DNA damage. To date, previous studies have shown that antigens encoded by human tumor viruses such as
SV40 large T antigen, adenovirus E1A and HPV E6 interact with p53 and disrupt its functional activity. In a
similar fashion, we now show that EBNA3C, one of the EBV latent antigens essential for the B-cell
immortalization in vitro, interacts directly with p53. Additionally, we mapped the interaction of EBNA3C with
p53 to the C-terminal DNA-binding and the tetramerization domain of p53, and the region of EBNA3C
responsible for binding to p53 was mapped to the N-terminal domain of EBNA3C (residues 130–190),
previously shown to interact with a number of important cell-cycle components, speciﬁcally SCFSkp2, cyclin A,
and cMyc. Furthermore, we demonstrate that EBNA3C substantially represses the transcriptional activity of
p53 in luciferase based reporter assays, and rescues apoptosis induced by ectopic p53 expression in SAOS-2
(p53−/−) cells. Interestingly, we also show that the DNA-binding ability of p53 is diminished in the presence
of EBNA3C. Thus, the interaction between the p53 and EBNA3C provides new insights into the mechanism(s)
by which the EBNA3C oncoprotein can alter cellular gene expression in EBV associated human cancers.© 2009 Elsevier Inc. All rights reserved.IntroductionThe p53 tumor suppressor gene is believed to be among the most
frequently mutated genes in human cancer including lung, colorectal,
and breast cancer, as well as many others. p53 responds to DNA
damage or other various cellular stresses to reduce cell growth and
promote programmed cell death (Gottlieb and Oren, 1996; Ko and
Prives, 1996; Levine 1997; Vogelstein et al., 2000). p53 accomplishes
its antiproliferative properties through its action as a DNA-binding
transcriptional activator, to induce expression of downstream target
genes, which includes p21/waf1/cip1 (El-Deiry et al., 1993), GADD45
(Kastan et al., 1992), cyclin G (Okamoto and Beach, 1994), bax
(Miyashita and Reed, 1995), IGF-BP3 (Buckbinder et al., 1995), and
mdm2 (Wu and Levine,1994). These target gene products are involved
in cell-cycle arrest, apoptosis, and regulation of p53 function in cells
exposed to genotoxic stresses.
The expression level of p53 is predominantly regulated through
the ubiquitin-proteasome pathway by the speciﬁc E3 ubiquitin ligase,
Mdm2 and is maintained at low levels during normal homeostasisrtson).
ll rights reserved.(Tang et al., 2006). However, in response to cellular stresses such as
DNA damage, hypoxia and oncogene activation, p53 is stabilized and
activated through several mechanisms that block the Mdm2–p53
interaction (Sherr and Weber, 2000; Stommel and Wahl, 2004; Tang
et al., 2006). Interestingly, mdm2 is one of the genes which is
transactivated by p53 (Wu and Levine, 1994), thus not only is Mdm2
required for keeping p53 in check under non-stress conditions and
releasing it when appropriate, it is also part of an auto-regulatory
feedback loop (Prives, 1998).
The Epstein–Barr virus (EBV) is a γ-herpesvirus that produces an
asymptomatic infection in the majority of the global population
(Rickinson and Kieff, 2002). However, EBV is also associated with
several human malignancies of B-cell origin, including Burkitt's
lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, immuno-
blastic B lymphoma in AIDS patients, post-transplant associated
lymphomas, and some gastric carcinomas (Ambinder, 1990; Rickinson
and Kieff, 2002). Although, the precise mechanisms of these EBV
mediated diseases are not yet clear, it has been suggested that
interference with cell-cycle checkpoints and responses to DNA
damage by EBV encoded oncoproteins may play vital roles in B-cell
lymphomagenesis (O'Nions and Allday, 2004). In vitro, EBV can
transform normal resting human B-cells to continuously proliferating
lymphoblastoid cell lines (LCLs). The resulting LCLs express nine viral
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EBNA3A, EBNA3B, EBNA3C, and EBNALP) and three integral mem-
brane proteins (LMP1, LMP2A, and LMP2B) (Rickinson and Kieff,
2002). Four viral antigens, EBNA2, LMP1, EBNA3A, and EBNA3C have
been shown to be absolutely essential for EBV transformation of
human B-cells and establishment of latency in vitro (Cohen et al.,
1989; Hammerschmidt and Sugden, 1989; Kaye et al., 1993;
Tomkinson et al., 1993).
EBNA3C has been shown to play a complex regulatory role in the
transcription of several viral and cellular genes. EBNA3C targets the
cellular transcription factor, RBPJk to antagonize EBNA2 mediated
transactivation (Johannsen et al., 1996; Robertson et al., 1995, 1996).
However, conversely, EBNA3C cooperates with EBNA2 in the activa-
tion of the major viral LMP1 promoter via interactionwith the cellular
transcription factor, Spi-1/Spi-B (Zhao and Sample, 2000). EBNA3C is
also involved in the regulation of chromatin remodeling by recruiting
both histone acetylase and deacetylase activities (Knight et al., 2003;
Radkov et al., 1999; Subramanian et al., 2002a). Furthermore, EBNA3C
associates with Nm23-H1, a metastasis suppressor protein, and
modulates the transcription of cellular genes involved in cell
migration and invasion (Kaul et al., 2007; Subramanian et al., 2001,
2002b). In addition to its transcriptional functions, it has been
reported that EBNA3C has cell-cycle regulatory functions, presumably
mediated by direct protein–protein interactions (Knight and Robert-
son, 2004; Knight et al., 2004, 2005a, 2005b). EBNA3C expression
stimulates cyclin A-dependent kinase activity (Knight et al., 2004;
Knight and Robertson, 2004), and recruits the SCFSkp2 ubiquitin ligase
complex and also regulates the stability of vital cell-cycle modulatory
components, such as p27 (Knight et al., 2005b) and Rb (Knight et al.,
2005a) in transiently or stably transfected cells. Paradoxically, a recent
study showed that EBNA3C stabilizes another cellular oncoprotein,
cMyc (Bajaj et al., 2008).
Overall, oncogenic viruses are able to disrupt cell-cycle check-
points induced by genotoxic stress (O'Nions and Allday, 2004). Among
the human DNA tumor virus oncoproteins, SV40 large T antigen,
adenovirus E1A and HPV E6 have all been shown to form a complex
with p53 and disrupt p53-dependent transcriptional activity through
distinct mechanisms, which can contribute to virus mediated
oncogenesis (Lechner et al., 1992; Steegenga et al., 1996). Thus, it
seems common for viruses to contribute to carcinogenesis by
repressing the activities of p53. Several studies indicate that EBV
does not speciﬁcally target p53 in LCLs (O'Nions and Allday, 2003;
Wade and Allday, 2000), however, recent studies have demonstrated
that EBV encoded antigens can interfere with cell-cycle checkpoints at
both G1/S (Knight et al., 2004; Knight and Robertson, 2004) and G2/
M (Choudhuri et al., 2007) to mediate cellular transformation and
EBNA1 may contribute to this process by interacting with a cellular
deubiquitination enzyme leading to reduction in p53 levels (Holowaty
et al., 2003; Saridakis et al., 2005). Given the nature of p53 as a
common target for several viral oncoproteins, it is reasonable to
speculate that p53 may also be a target of EBNA3C.
In this report, we explored the effects of EBNA3C on the p53 tumor
suppressor. In vitro binding assays as well as in vivo immunoprecipita-
tion experiments in EBV infected LCLs showed that EBNA3C forms a
stable complex with p53. The interaction occurs at two distinct
regions of p53, which includes the central DNA-binding domain and
C-terminal regulatory domain. Additionally, the region of EBNA3C that
binds to p53 was mapped at the amino-terminal region (residues
130–190), which includes the leucine zipper motif and was previously
shown to include the binding site of numerous cellular components,
such as RBP-Jκ, cyclin A, Rb, SCFSkp2 and cMyc (Bajaj et al., 2008;
Knight et al., 2004, 2005a, 2005b; Robertson et al., 1996). The addition
of p53 molecule in this repertoire of cellular components further
reveals the signiﬁcance of this binding domain of EBNA3C in
deregulating the cell-cycle. Similar to adenovirus E1A and HPV
oncoprotein E6, here we demonstrate that EBNA3C can efﬁcientlyrepress p53-mediated transcriptional activity as well as DNA-binding
ability. Additionally, we conﬁrm the manifestation of EBNA3C
mediated repression on p53 functional activity by rescuing cells
from p53-dependent apoptosis. Based on these results, we propose
that EBNA3C modulates the functional activities of p53 in terms of its
transactivation activity as well as induction of apoptosis, which may
contribute to the oncogenic properties of EBNA3C in EBV infected
cells.
Results
EBNA3C interacts directly with p53 in vitro
A number of tumor virus antigens have been shown to interact
directly with p53 for disrupting its function. The role of EBV latent
antigens in regulating p53 has so far been elusive in the context of
latency III; however studies have sown that EBNA1 can protect infected
cells from apoptosis by lowering the levels of p53 via interaction with
a deubiquitination enzyme (Holowaty and Frappier, 2004; Holowaty
et al., 2003; Saridakis et al., 2005). It would be interesting to
investigate whether or not the essential EBV antigen, EBNA3C can
similarly deregulate this cellular master regulator, p53 either by direct
protein–protein interaction or via an indirect mechanism.
To determinewhether EBNA3C is able to interact directly with p53,
we performed in vitro binding assays. A GST-p53 expression construct
was bacterially expressed and the fusion protein was incubated with
in vitro translated 35S-labeled EBNA3C (Fig. 1A). GST-p53 beads
precipitated a signiﬁcant amount of radiolabeled EBNA3C, while a
negligible signal was observed with GST control beads (Fig. 1A;
compare lane 3 with lane 2). To corroborate the result of the in vitro
binding study in a more biologically relevant setting, we conducted
parallel GST pull-down experiments, using cell lysates prepared from
two transformed EBV positive lymphoblastoid cell lines—LCL1 and
LCL2, EBV negative Burkitt's lymphoma cell line (BJAB) and BJAB cells
stably expressing EBNA3C (two clones—BJAB E3C #7 and E3C #10). As
shown in Figs. 1B and C, EBNA3C strongly interacted with the GST-p53
fusion protein but not with the GST control in these pull-down assays.
These results support the initial observation that EBNA3C interacts
directly with p53 in vitro and can form a complex with p53 in lysates
of human cells.
EBNA3C associates with p53 and forms a complex in human cells in vivo
To corroborate the in vitro binding data, we performed next a
series of in vivo co-immunoprecipitation experiments. Both HEK 293
and DG75 cells were co-transfected with expression constructs for
ﬂag-tagged EBNA3C and p53 tagged with myc epitope. Immunopre-
cipitation analyses as shown in Figs. 2A–D clearly demonstrated that
EBNA3C strongly associated with p53 in vivo. A distinct band of myc-
tagged p53 was detected in the anti-ﬂag immunoprecipitated lane by
immuno-blot against myc-p53 (Figs. 2A and C bottom panels). In the
reverse experiments, the ﬂag-tagged EBNA3C was also clearly
detected in the anti-myc immunoprecipitated sample (Figs. 2B
and D, bottom panels). Importantly, EBNA3C or p53 binding was not
detected in control samples using normal mouse serum (designated
as PC in Figs. 2A–D) supporting the speciﬁcity of these complexes in
cells. To verify further, if this binding was signiﬁcant at endogenous
levels, p53 was immunoprecipitated from EBV negative BJAB cells and
two different EBV transformed lymphoblastoid cell lines (LCL1 and
LCL2). Again, the immunoprecipitation of p53 complexes resulted in a
reproducible co-immunoprecipitation of EBNA3C, but not with the
control serum, supporting the existence of this stable complex in EBV
transformed B lymphocytes (Fig. 2D). Hence, analysis of the data from
the ectopic expression system as well as cell lines endogenously
expressing p53 and EBNA3C demonstrated the strong association of
p53 with EBNA3C in complex in EBV infected cells.
Fig. 1. EBNA3C forms a stable complex with p53 in vitro. (A) GST-p53 fusion protein was expressed in E. coli and puriﬁed with glutathione Sepharose beads. Full-length EBNA3C was
labeled with 35S methionine by in vitro translation and incubated with either GST control or GST-p53 beads normalized by Coomassie staining. 5% of in vitro translation (IVT) input
was used for comparison. Precipitated proteins were resolved by SDS-PAGE, and bands were visualized with a phosphorimager screen. Relative density was quantiﬁed using Storm
850 imaging system. (B, C) Either GSTcontrol or GST-p53 beads were incubatedwith lysates prepared from either 50million (B) lymphoblastoid cell lines (LCL1 and LCL2) or (C) BJAB
cells and BJAB cells stably expressing EBNA3C (two clones—BJAB EBNA3C#7 and BJAB EBNA3C#10). Approximately 5% of the lysed cells were saved as input and precipitated protein
complexes were resolved by 7% SDS-PAGE. EBNA3C was detected by western blot with the speciﬁc monoclonal antibody (A10) followed by an infrared-tagged secondary antibody
and scanned using Odyssey imager. All panels are representative gels from similar repeat experiments.
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of p53
To determine the precise binding site of EBNA3C that interacts
with p53, we utilized a series of EBNA3C truncated constructs
(residues 1–365, 366–620, and 621–992) (Bajaj et al., 2008). These
EBNA3C truncations were in vitro translated and subjected to GST-
pull-down assays. As shown in Fig. 3A, GST-p53 strongly precipitated
the N-terminal domain of EBNA3C (residues 1–365) (Fig. 3A, left
panel), whereas neither the middle part (residues 366–620) nor the
C-terminal domain (residues 621–992) was seen in GST-p53 pull-
down samples (Fig. 3A, middle and right panels, respectively). AllFig. 2. EBNA3C interacts with p53 in vivo. (A, B) Either 10 million HEK 293 cells or (C, D) 20
Cells were harvested at 36 h post-transfection and approximately 5% of the lysed cells were
antibody. Lysates and IP complexes were resolved by SDS-PAGE and immuno blotted with
antibodies. PC: preclear; prior to set up IP, cell lysates were precleared with normal mouse se
collected at exponential growth phase and lysed in RIPA buffer. Protein complexes were imm
resolved by 7% SDS-PAGE and western blotting for the indicated proteins was done by stripp
from similar repeat experiments.EBNA3C truncations failed to bind with the GST control, indicating
that the observed interaction was speciﬁc for p53. To map the
interacting domain within the N-terminal region of EBNA3C in more
detail, bacterially expressed smaller truncations of GST-fused EBNA3C
proteins were tested for their ability to bind with full-length p53. As
shown Fig. 3B, in vitro translated 35S-radiolabeled p53 showed strong
binding to GST-fused EBNA3C residues 130–160 and 160–190 (Fig. 3B,
top panel, lanes 4 and 5, respectively), but no signiﬁcant binding was
observed either with the GST control or EBNA3C residues 90–130 (Fig.
3B, top panel, lanes 2 and 3, respectively). Coomassie staining of a
parallel gel indicated the levels of various GST proteins used in this
binding assay (Fig. 3B, bottom panel). These results subsequentlymillion DG75 cells were co-transfected with ﬂag-tagged EBNA3C and myc-tagged p53.
saved as input and remaining were immunoprecipitated (IP) with 1.5 μg of appropriate
the indicated antibodies. The same blots were stripped and reprobed with appropriate
rumwith protein A/G beads. (C) Either 50 million BJAB cells or LCLs (LCL1 and 2) were
unoprecipitated (IP) with 2.0 μg p53 speciﬁc antibody (DO-1, Santa Cruz). Samples were
ing and reprobing the same membrane. PC: preclear. All panels are representative gels
Fig. 3.N-terminal domain of EBNA3C binds to C-terminal domain of p53. (A–C) 35S-radiolabeled either full-length (C) or different EBNA3C truncated fragments (A) or full-length p53
(B) was in vitro translated using a T7 TNT translation kit. All 35S-radiolabeled in vitro translated proteins in binding buffer were precleared by rotating with GST-beads for 1 h at 4 °C.
The binding reaction mixture was set up with either bacterially puriﬁed GST control or the indicated GST fusion proteins. Reactions were resolved by appropriate SDS-PAGE, exposed
to phosphorimager plate, and scanned on a Storm 850 imaging system. The amount of protein bound in each GST-pull-down sample was quantiﬁed with ImageQuant software
(Molecular Dynamics). Coomassie staining of SDS-PAGE resolved puriﬁed GST proteins is shown (B and C, bottom panels). All panels are representative gels from similar repeat
experiments. (D) Schematics illustrate different structural domains of EBNA3C and p53. Grey broken lines indicate the respective binding domain(s) of two proteins.
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shown to interact with several important cellular molecules, also
forms a stable complex with p53, signifying the importance of this
region in the deregulation of the cell-cycle in EBV infected cells.
EBNA3C binds p53 at the DNA-binding and tetramerization domain
While little is known about the tertiary and quaternary structure of
EBNA3C, p53 is well understood structurally in the context of
structure–function relationships. The p53 protein can be divided
roughly three distinct domains—the N-terminal domain containing
the transactivation domain, the central core containing its sequence-
speciﬁc DNA-binding domain, and the multifunctional C-terminal
domain (Adler et al., 1997; Hupp et al., 1993). The acidic activation
domain lies within residues 1–43, although neighboring sequences
are also likely to contribute to the transcriptional activity of p53. The
central core of p53 lies within residues 100–300, and the C-terminus
of p53 lies within residues 300–393. To determine the interacting
domain(s) of p53 with EBNA3C, different GST-fused truncated
mutants of p53 were generated and tested for their ability to bind
radiolabeled EBNA3C using in vitro binding experiments. The results
of these binding studies clearly demonstrated that that full-length
p53, the central domain (residues 100–300) and the C-terminal
domain (residues 300–393) can tightly interact with EBNA3C (Fig. 3C,top panel, lanes 3, 5 and 6, respectively), whereas no binding was
observed with either GST control or the N-terminal transactivation
domain (Fig. 3C, top panel, lanes 2 and 4, respectively). Thus, the
amino acid region 100–393 of p53 which encompasses both DNA-
binding and tetramerization domains, is responsible for the interac-
tion with EBNA3C, however, particularly, the tetramerization domain
of p53 showed stronger (1.7 fold higher) interaction with EBNA3C.
Coomassie staining of a parallel gel indicated the amounts of different
GST-p53 proteins used in this binding assay (Fig. 3C, bottom panel).
EBNA3C colocalizes with p53 in the nucleus of EBV transformed LCLs
To further support the in vitro and in vivo binding data and also to
visualize the interaction between p53 and EBNA3C under physiolo-
gically relevant conditions, colocalization experiments were per-
formed using EBV infected LCL1 and LCL2 cells (Fig. 4, middle and
bottom panels, respectively). BJAB cells represent EBV negative cells
not expressing EBNA3C (Fig. 4, top panels). Immunoﬂuorescence
staining using speciﬁc monoclonal antibodies against EBNA3C and
p53 showed that both proteins were tightly nuclear, demonstrating a
stippled, punctate pattern staining with the exclusion of nucleoli (Fig.
4). In both EBV positive cell lines, p53 clearly colocalized with EBNA3C
at a number of spots, as visualized by yellow ﬂuorescence. These data
corroborate the in vivo and in vitro association studies between p53
Fig. 4. EBNA3C colocalizes with p53 in EBV positive cell lines. (A) EBV negative Burkitt's lymphoma cell line, BJAB, and two EBV transformed cell lines—LCL1 and LCL2 were air-dried
onto slides and ﬁxed using a 1:1 mixture of acetone andmethanol. Endogenously expressed p53 was detected using mouse monoclonal antibody (DO-1,1:200 dilution) respectively,
followed by anti-mouse Alexa Fluor 594 (red), and EBNA3Cwas detected using EBNA3C-reactive human serum (1:150 dilution) followed by anti-human Alexa Fluor 488 (green). EBV
negative BJAB cells were used as EBNA3C null control cell lines. (B) 10 million BJAB cells were transfected with GFP-tagged EBNA3C truncated mutants—residues 1–365 (top panels)
and residues 366–620 (bottom panels). Endogenous p53 was detected using DO-1 antibody as B. The nuclei were counterstained using DAPI (blue). The images were sequentially
captured using an Olympus confocal microscope. All panels are representative pictures from similar repeat experiments.
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compartments in the cell nucleus (Fig. 4, second, third and fourth
panels, third column). For additional proof, the colocalization study
was extended using the truncated domains of EBNA3C, the N-terminal
domain (residues 1–365) and as a negative control, the middle part
(residues 366–620), which did not interact with p53 in GST-binding
assays or in in vivo co-immunoprecipitation assays. EBV negative
Burkitt's lymphoma cell line, BJAB was transiently transfected with
EBNA3C constructs expressing GFP-tagged residues 1–365 and 366–
620. Speciﬁc monoclonal antibody against p53 was used to detect
endogenous p53. The results presented in Fig. 4B clearly demonstrated
that p53 colocalized with N-terminal domain of EBNA3C (Fig. 4B, top
panel), whereas in contrast, the central domain EBNA3C (residue 366–
620) showed negligible colocalizationwith p53 (Fig. 4B, bottom panel).EBNA3C inhibits p53 mediated transactivation
Since the transcriptional activity of p53 is important for p53-
mediated regulation (Adimoolam and Ford, 2003), we investigated
whether EBNA3C represses p53-dependent transcriptional activity.
Reporter constructs containing thirteen consensus p53-binding sites
promoter fused to the luciferase gene were transiently co-transfected
into p53-null cells (SAOS-2) with the empty vector or plasmid
expressing EBNA3C. In the presence of EBNA3C, p53 transactivation
activity was signiﬁcantly reduced in SAOS-2 cells (Fig. 5A). This
reduction in p53 transactivation activity was not cell speciﬁc as in
BJAB, a B-cell line, EBNA3C was also found to repress the transactiva-
tion function of p53 using the same reporter construct (data not
shown). These results indicate that EBNA3C can suppress p53-
Fig. 5. EBNA3C represses p53 mediated transcriptional activity. (A–B) Approximately 0.4×106 SAOS-2 (p53−/−) cells were co-transfected with 0.25 μg of the promoter construct
containing p53 responsive element and 0.5 μg of myc-tagged p53 plus either vector control or (A) increasing amount of ﬂag-tagged EBNA3C expressing constructs (0, 0.25, 0.5, and
1.0 μg respectively) (B) ﬂag-tagged different truncated mutants of EBNA3C using Lipofectamine 2000 (Invitrogen). At 24 h post-transfection, cells were harvested and lysed for
luciferase assays. Total amount of proteins were normalized by Bradford assay. Increasing amounts of EBNA3C show proportional increment in luciferase activity. The representative
plot is a mean of two independent experiments. Error bar represents standard deviation (SD). Bottoms panels indicate the fractions of the cell lysates were resolved by SDS-PAGE to
demonstrate the expression levels of p53 and EBNA3C. GAPDH blot was done for loading control.
Fig. 6. EBNA3C reduces DNA-binding ability of p53. A probe containing the p53 binding
sequence (5′-AGGAAGAAGACTGGGCATGTCTGGGCA-3′) was labeled by Klenow ﬁll-in
reactionwith [α-32P]dCTP and used for EMSA in presence and absence of EBNA3C. Lanes
1 and 6, probe incubated with nuclear extracts (NE) isolated from SAOS-2 (p53−/−)
cells transfected with empty vector control; lanes 2 and 7, probe incubated with myc-
tagged p53 expressing NE, showing band shift due to p53 binding (⁎); lane 3, probe
with 200-fold molar excess of cold speciﬁc competitor, which abolished completely the
p53 speciﬁc shift; lane 4, probe with 200-fold molar excess of cold mutant probe
competitor showing no effect on p53 speciﬁc shift; lane 5, probe incubated with p53
expressing NE and monoclonal antibody against p53 (DO-1), which super-shifted the
p53 speciﬁc probe (⁎⁎); lane 8, probe incubated with NE expressing both p53 and
EBNA3C, reduced the p53 speciﬁc band intensity most likely due to formation of a stable
inhibitory complex between p53 and EBNA3C in vivo (arrowhead).
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EBNA3C resulted in a dose-dependent inhibition of p53 transactiva-
tion (Fig. 5A, bar diagram). The expression levels of EBNA3C, p53, and
GAPDH as a loading control, also were analyzed by western blotting
(Fig. 5A, bottom panels). EBNA3C expression did not interferewith the
expression levels of p53 and GAPDH (Fig. 5A), and so indicates that
EBNA3C mediated repression of p53 transactivation is not likely to
occur by promoting the degradation of p53. To further deﬁne the
domain or domains of EBNA3C important for this activity and also to
determine if the binding domain of EBNA3C is essential for inhibition
of p53-mediated transactivation, the aforementioned experiments
were extended using different truncated domains of EBNA3C. Two
EBNA3C truncated mutants were tested, the N-terminal binding
region of EBNA3C (residues 1–365) showed almost similar ability to
repress p53-dependent transcriptional activity as seen in case of wild-
type EBNA3C (Fig. 5B, bar diagram, compare bars 3 and 4)whereas the
non-binding middle region of EBNA3C (residues 366–620) had no
signiﬁcant effect (Fig. 5B, bar diagram, compare bars 4 and 5). Overall
the data suggest that EBNA3C represses the p53 transactivation
activity by forming a complex with p53 perhaps by interfering with its
ability to access the target promoters.
EBNA3C can inhibit p53 sequence-speciﬁc DNA-binding activity
Repression of the p53 transactivation activity by EBNA3C plus the
binding data showing that the central DNA-binding domain of p53 is
involved in p53-EBNA3C interaction, led us to further investigate
whether EBNA3C exerts any potential inhibitory role on the DNA-
binding ability of p53. We performed electrophoretic mobility shift
assay (EMSA) experiments to resolve whether any changes in DNA-
binding activities can be detected when p53 binds to its respective
DNA-binding site, in presence of EBNA3C (Fig. 6). Nuclear extracts
from SAOS-2 (p53−/−) cells transfected with either pA3M-p53,
encoding myc-tagged p53 and pcDNA empty vector or pcDNA-
EBNA3C, expressing full-length untagged EBNA3C, were incubated
Fig. 7. EBNA3C blocks p53 induced apoptosis in p53 null cell line SAOS-2. (A, B) SAOS-2 (p53−/−) cells were transiently transfected either with vector control, or constructs
expressing untaggedwild-type EBNA3C and p53 alone, or p53 and EBNA3C together. After 48 h of transfection, cells were harvested, ﬁxed and levels of apoptotic cells in each samples
were analyzed by ﬂow cytometry (Becton-Dickinson). A total of 20,000 events were analyzed for each sample. Datawere analyzed using theModFIT model program (Verity Software
House). The representative plot is a mean of three independent experiments. Error bar represents SD. EBNA3C (top panel) and p53 (middle panel) protein expression levels were
judged by western blot. Equal protein loading was analyzed GAPDH (bottom panel) blot. (C) A schematic representation of p53 mediated transcriptional regulation in EBV negative
(−) and positive (+) cells. In response to genotoxic stress, p53 achieves its antiproliferative properties through its action as a DNA-binding transcriptional activator, to induce
expression of numerous downstream target genes, involved in cell-cycle arrest and apoptosis. In EBV positive cells, EBNA3C potentially inhibits p53 mediated transcriptional activity
via forming a stable complex with p53. p53 RE: p53 responsive element.
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using EMSA. Nuclear extracts containing p53 reduced the mobility of
the radiolabeled probe, as expected (Fig. 6, compare lane 2 with lane
1). The mobility was further super-shifted with an anti-p53 mono-
clonal antibody, suggesting that the speciﬁcity of the shift was due to
the presence of p53 (Fig. 6, compare lane 5 with lane 2). Additionally,
the p53-speciﬁc shift was competed with the addition of a 200×cold
speciﬁc competitor (Fig. 6, compare lane 3 with lane 1), whereas, it
was not affected by a similar amount of a mutant cold competitor (Fig.
6, compare lane 4 with lane 1). Importantly, in a separate experiment,
addition of nuclear extracts containing both p53 and EBNA3C to the
binding reaction, resulted in a signiﬁcant decrease (∼50%, Fig. 6 bar
diagram) in the observed intensity of the p53-speciﬁc shift (Fig. 6,
compare lane 8 with lane 7). These results strongly suggest that the
EBNA3C-p53 complex may inﬂuence wild-type p53 activity by
inhibiting the sequence-speciﬁc DNA-binding activity of p53. More-
over, the complex between EBNA3C and p53 may alter the conforma-
tion of p53 in a way analogous to p53 missense mutants found in
human cancers. Interestingly, the interaction between EBNA3C and
another cellular transcription factor, cMyc enhances its transcriptional
activity probably via increasing its DNA-binding speciﬁcity (Bajaj et
al., 2008). These contrasting results indicate that the functional
consequence of EBNA3C on gene expression may depend on its
interaction with speciﬁc cellular transcription factors.
p53-mediated apoptosis in SAOS-2 cells is suppressed by EBNA3C
expression
To determine the signiﬁcance of EBNA3C in terms of its direct
regulation of p53 function, we veriﬁed whether or not EBNA3C could
affect p53mediated apoptosis. It has been shown earlier that the over-
expression of p53 can lead to apoptosis in p53-null SAOS-2 cells
(Schuler et al., 2000). In order to determine if EBNA3C expression
affects the ability of p53 to mediate apoptosis, the levels of apoptotic
cells in the transiently transfected SAOS-2 cells with constructs
expressing either wild-type p53 or EBNA3C alone, or p53 and EBNA3C
together, were examined. Further, in order to monitor the transfection
efﬁciency and viability of cells, a GFP expression construct was co-
transfected and checked under ﬂuorescent microscopy at 48 h post-
transfection which revealed about 95% transfection efﬁciency (data
not shown). Apoptosis was detected in approximately 25% of SAOS-2
cells expressing p53, which was signiﬁcantly higher than the basal
level of apoptotic cells (6–7%) expressing either vector control or
EBNA3C alone (Figs. 7A, B, histogram and bar-representation).
However, in presence of EBNA3C, p53 mediated apoptosis was
drastically inhibited and was seen in only 10–12% of the cells, a
decrease in approximately 50% (Figs. 7A, B, histogram and bar-
representation). Thus, these data revealed that EBNA3C can provide a
signiﬁcant protection from p53-dependent apoptosis. The expression
levels of EBNA3C, p53, and GAPDH as a loading control, were also
analyzed by western blotting (Fig. 7B, bottom panels).
Discussion
The tumor suppressor p53 protects mammalian cells from
malignant transformation by inducing either cell-cycle arrest or
apoptosis in response to viral infection among other genotoxic
stresses (Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine 1997;
Vogelstein et al., 2000). Not surprisingly, either p53 itself or cellular
factors involved in downstream activities are inactivated by various
viral antigens either by releasing cells from cell-cycle checkpoints or
by protecting cells from p53-dependent apoptosis (El-Deiry et al.,
1993; Waldman et al., 1995; Yin et al., 1997). While cell-cycle arrest
depends on the ability of p53 to induce the transcription of target
genes such as the CDK inhibitor p21 (El-Deiry et al., 1993), apoptosis
depends on induction of a distinct class of target genes, including bax,puma, perp, and many others (Vousden and Lu, 2002). Several virus
encoded antigens including SV40 large T antigen, adenovirus E1A and
E1B, hepatitis B virus (HBV) X protein, and HPV E6 and E7 interferewith
p53 function via multiple mechanisms (Lechner et al., 1992; Martin and
Berk, 1998; Mietz et al., 1992; Scheffner et al., 1990; Wang et al., 1994;
Massimi and Banks, 1997). Large T antigen and E1B was found to
interact with p53 and enhance its stability, however surprisingly its
functional activity was inhibited (Martin and Berk, 1998; Mietz et al.,
1992). On the other hand, HPV E6 antigen induces the p53 degradation
utilizing ubiquitin-proteasome mediated pathway (Mietz et al., 1992).
In addition, the HBV X protein has been shown to interact with p53 and
inhibits its functional activity in multiple ways (Wang et al., 1994).
Similar to smaller DNA viruses, herpesvirus family members also
have been shown to manipulate p53. For instance, the CMV IE2
protein (Castillo et al., 2000), the KSHV ORF K8 protein (Park et al.,
2000), and the HHV6 ORF 1 protein (Doniger et al., 1999) all inhibit
the transactivation activity of p53. Also KSHV LANA and EBV encoded
lytic antigen BZLF1 and latent antigen LMP1 have been shown to
interfere with p53 functional activity (Friborg et al., 1999; Mauser et
al., 2002; Fries et al., 1996). Moreover, EBNA1 has also been shown to
contribute to regulation of p53 level through interaction with a
deubiquitination enzyme and so may contribute to regulation of its
transcription and apoptotic activities (Holowaty et al., 2003; Saridakis
et al., 2005). However, in comparison to the effects of the smaller DNA
viruses, considerably less is known regarding the various mechanisms
by which herpesviruses inhibit the transcriptional function of p53.
Recent studies have established that an essential EBV encoded
latent antigen, EBNA3C (Rickinson and Kieff, 2002) strongly interferes
the functional consequences of multiple components which are
primarily involved in cell-cycle checkpoints at both G1/S (Knight et
al., 2004; Knight and Robertson, 2004; Bajaj et al., 2008) and G2/M
(Choudhuri et al., 2007). In contrast to the initial studies (Allday et al.,
1995), we now show that EBNA3C has potential inhibitory effects on
p53 functional activities. We speculate that the repressive effects of
EBNA3C on p53 function provide a more effective platform which
increases the efﬁciency of EBV mediated lymphomagenesis.
In vitro binding experiments suggested that EBNA3C and p53
physically interact, and this was supported by in vivo immunopreci-
pitation studies of cell lysates from EBV positive cell lines (LCL1 and
LCL2). Immuno-localization using speciﬁc antibodies against EBNA3C
and p53 showed a speckled nuclear localization of these two
molecules which were colocalized distinctly in EBV infected cells.
Additional mapping of the interacting domain of EBNA3C showed that
it associates with p53 via the same region, residues 130–190, which
has been implicated previously for interaction with several important
cellular components, including SCFSkp2, Rb, cMyc, cyclin A and RBPJκ
(Bajaj et al., 2008; Knight et al., 2004, 2005a, 2005b; Robertson et al.,
1996). The inclusion of p53 in the group of cellular components
modulated by this particular domain of EBNA3C further emphasizes
the importance of this critical domain for bypassing the cell-cycle
checkpoints in EBV infected cells.
We further delineated the domains of p53 that are involved in
binding to EBNA3C. In vitro binding experiment demonstrated that
EBNA3C interacts with p53 at two different regions—the core DNA-
binding domain and the C-terminal oligomerization domain. Three
major functional domains have been identiﬁed in p53: a N-terminal
transactivation domain (residues 1–80) (Candau et al., 1997; Fields
and Jang, 1990; Funk et al., 1992; Raycroft et al., 1990), a central
sequence-speciﬁc DNA-binding domain (residues 94–293) (Bargo-
netti et al., 1993; Halazonetis et al., 1993; Wang et al., 1993), and a C-
terminal oligomerization domain (residues 325–355) (Clore et al.,
1994; Jeffrey et al., 1995; Lee et al., 1994; Sakamoto et al., 1994;
Sturzbecher et al., 1992). In addition to the oligomerization domain,
the C-terminal domain contains two regions (residues 290–325 and
residues 356–393) which negatively regulate its DNA-binding activity
(Waterman et al., 1995; Hupp et al., 1992) through multiple
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Prives, 1995) and acetylation (Liu et al., 1999). In addition, evidence
supports that the highly positively charged C-terminal regulatory
domain may interact with the core DNA-binding domain and lock p53
in an inactive conformation (Muller-Tiemann et al., 1998). The critical
oligomerization domain of p53 showed the higher afﬁnity for EBNA3C,
suggesting that EBNA3C may be involved in regulation of p53
mediated transcriptional activity and its DNA-binding ability.
Results from the binding experiments and the colocalization
studies, prompted us to investigate further whether or not EBNA3C
has any effect on p53 functional activity. The ability to regulate the
luciferase expression from a reporter construct composing multiple
units of p53 responsive element was tested in presence and absence of
EBNA3C. Indeed the data showed that EBNA3C substantially blocks
p53 mediated transactivation. Other viral proteins have also been
shown to deactivate p53 mediated transactivation in a similar fashion
(Park et al., 2000; Doniger et al., 1999). The possibility of squelching
was excluded as we have previously shown that EBNA3C can
upregulate the transcription of the cMyc target gene, telomerase
reverse transcriptase (TERT) in promoter assays and that the effect
was dose responsive (Bajaj et al., 2008).
Modiﬁcations to the C-terminal domain, including deletion of the
last 30 amino acids (Hupp et al., 1992), protein binding (Hupp et al.,
1992), phosphorylation of Ser-315, Ser-378, and Ser-392 (Hupp and
Lane 1995; Takenaka et al., 1995; Wang and Prives, 1995), and most
recently, acetylation by CREB-binding protein CBP/p300 (Gu and
Roeder, 1997) were shown to enhance sequence-speciﬁc DNA-binding
of wild-type p53, possibly by inhibiting p53's C-terminal non-
sequence-speciﬁc DNA-binding activity (Anderson et al., 1997). CBP/
p300 along with p300/CBP-associated factor PCAF (Yang et al., 1996)
interacts with p53 and enhances its transcriptional activity (Avantag-
giati et al., 1997; Lill et al., 1997) through acetylation at multiple lysine
residues at C-terminal site. However, on the other hand deacetylation
of p53 by HDAC1-containing complex (Luo et al., 2000) led to
transcriptional deactivation. Moreover, its major negative regulator,
Mdm2 has also been shown to recruit HDAC1 activity towards p53,
which subsequently increases its ubiquitination and degradation (Ito
et al., 2002). Interestingly, EBNA3C has also been shown to interact
with both p300 (Subramanian et al., 2002a) and HDAC1 (Cotter and
Robertson, 2000). The interaction of EBNA3C with p300 and HDAC1
resulted in modulation of acetylation of cellular factors (Cotter and
Robertson, 2000). These ﬁndings lead us to speculate that EBNA3C
may regulate p53 acetylation for modulating its transcriptional
activity and DNA-binding ability via interaction with p300 and
HDAC1. The precise mechanisms of how EBNA3C acts on speciﬁc
lysine residues involved in acetylation or/and ubiquitination in EBV
scenario is currently under investigation in our laboratory. It would
also be interesting to investigate whether EBNA3C forms a ternary
complex with p53 and Mdm2 or p300 or HDAC1 for critically
modulating p53's activity.
Abundant evidence indicates that p53's ability to bind to DNA is
tightly linked to its physiological functions in tumor suppression
(Levine 1997). EMSAs using a DNA probe from the p21 promoter
containing the p53 binding site in the presence of nuclear extracts
containing p53 showed binding to the probe, which was super-shifted
by the addition of an anti-p53 antibody. The addition of EBNA3C to the
reaction largely reduced the p53-speciﬁc complex. Studies have
shown that the C-terminal regulatory domain negatively regulates
p53's DNA-binding ability; perhaps by maintaining p53 in the low
afﬁnity DNA-binding state (Hupp et al., 1992; Waterman et al., 1995),
raises the possibility that the inactivation of p53 activity by EBNA3C, is
likely due to the formation of a stable complex between the p53 C-
terminal negative regulatory domain and EBNA3C.
Our data also indicated that expression of EBNA3C was able to
abrogate p53-mediated apoptosis in the p53 null cell line, SAOS-2.
Since EBNA3C interacts with complexes that include corepressors andsilencers of transcription, it is tempting to speculate that EBNA3C
forms part of a multi-protein repression complex that inhibits
transcription mediated by p53. Based on our ﬁndings in reporter
assays, it is likely that EBNA3C interferes with p53-mediated apoptosis
by potentially inﬂuencing its transcriptional activation. A recent study
demonstrated that EBNA3C functionally cooperate to repress the
expression of the proapoptotic Bcl-2-family member Bcl-2-interacting
mediator of cell death (Bim) (Anderton et al., 2008). Alternatively
EBNA3C may inhibit p53 dependent apoptosis by disrupting protein–
protein interactions between p53 and other cellular factors involved in
the apoptotic pathway or directly interacting with proteins involved.
We are working on deciphering the mechanism(s) that leads to this
inhibition.
This study is an initial report showing that EBNA3C directly
interacts with p53 in vitro and associates in a complex in vivo. This
interaction of EBNA3C with p53 warrants further investigation as p53
controls the progression of the cell-cycle by regulating the genetic
integrity. The repression of p53 function by EBNA3C could result in
increased genetic instability, which may directly contribute to EBV
mediated cellular transformation.
Materials and methods
Plasmids, cell lines and antibodies
pA3F-EBNA3C constructs encoding either full-length or EBNA3C
truncations residues 1–365, 366–620, and 621–992 with C-terminal
ﬂag-tag have been described previously (Bajaj et al., 2008). The p53
reporter plasmid pGL-3 contains 13×p53-binding sites upstream of
the luciferase gene and was constructed by EcoRV insertion of p53-
binding sequences into the pGL-3 luciferase reporter plasmid (Wang
and El-Deiry, 2003). The p53 expression vector pC53-C1N3 carries a
wild-type humanp53 genewith a proline polymorphism at residue 73
and is controlled by the cytomegalovirus promoter (gift from Gary J.
Nabel, National Institutes of Health, Bethesda, MD). pGEX-p53
expresses an N-terminal glutathione S-transferase (GST)-p53 fusion
protein and was derived from pGEX-2T (Amersham Pharmacia, Inc.,
Piscataway, NJ) by insertion of human p53 cDNA (gift from Gary J.
Nabel, National Institutes of Health, Bethesda, MD) at the BamHI and
EcoRI sites. pA3M-p53 was generated by cloning PCR-ampliﬁed p53
cDNA using pGEX-p53 as a template into the previously described
vector pA3M (Knight et al., 2003; Bajaj et al., 2008) at EcoRI and NotI
sites. GST-p53 deletion constructs were constructed by insertion of
PCR fragments into the pGEX-5x-1 backbone (gift from Shelley L.
Berger, The Wistar Institute, Philadelphia, PA). Constructs expressing
GFP-tagged either EBNA3C residues 1–365 or 366–620 mutants were
prepared by cloning PCR-ampliﬁed fragments into pEGFP-C1 vector
(BD Biosciences Clontech) at EcoRI and SalI restriction sites. All
constructs and mutations were veriﬁed by DNA sequencing (Uni-
versity of Pennsylvania DNA sequencing facility).
Human embryonic kidney cell line, HEK 293was obtained from Jon
Aster (Brigham and Woman's Hospital, Boston, MA) (Aiello et al.,
1979). p53-null cell line SAOS-2 is derived from human osteosarcoma
and was obtained from Jon Aster (Brigham and Women's Hospital,
Boston, MA, USA). EBV negative Burkitt's lymphoma cell lines BJAB
and DG75 were provided by Elliot Kieff (Brigham and Woman's
Hospital, Boston, MA). LCL1 and LCL2 are in vitro-transformed EBV
positive cell lines. BJAB cells expressing EBNA3C and BJAB neo control
were generated previously by transfecting with either pZipneo
eukaryotic expression vector with EBNA3C cDNA or vector alone
(Robertson et al., 1995). The adherent cell lines (HEK 293, U2OS and
SAOS-2) were grown in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 5% bovine growth serum, 25 U/ml penicillin,
50 μg/ml streptomycin, and 2 mM L-glutamine. All B-cell lines were
grown in RPMI 1640 medium (HyClone) supplemented as Dulbecco's
modiﬁed Eagle's medium.
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reactive to EBNA3C were prepared from their respective hybridoma
culture (Knight et al., 2003; Bajaj et al., 2008). Mouse monoclonal
anti-p53 antibody DO-1 and mouse monoclonal anti-ﬂag antibody
were purchased from Santa Cruz Biotechnology, Inc and Sigma
respectively.
Transfection
HEK 293, BJAB and DG75 cells were transfected by electroporation
with a Bio-Rad Gene Pulser II electroporator. 12–15×106 cells were
harvested at exponential growth phase, collected, washed in phos-
phate-buffered saline (PBS; Hyclone, Inc., UT) and resuspended in
400 μl of the appropriate medium containing DNA for transfection
(Knight and Robertson, 2004). Resuspended cells were transferred to
a 0.4-cm gap cuvette and electroporated at 975 μF and 210 V for HEK
293 cells or 975 μF and 220 V for B-cells. Transfected cells were
transferred to a 100 mm Petri dish containing 10 ml of complete
medium and incubated at 37 °C in a humidiﬁed environment
supplemented with 5% CO2. Unless otherwise indicated, transfected
cells were harvested after 36 h and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed with
5% of the total normalized protein lysate.
Puriﬁcation of GST fusion proteins
Puriﬁcation of GST fusion proteins were performed essentially as
described previously (Bajaj et al., 2008) with some modiﬁcation.
Brieﬂy, Escherichia coli BL21 (DE3) cells were transformed with the
plasmid constructs for each glutathione S-transferase (GST) fusion
protein as described in the text. Single colonies were picked and
grown overnight in 3 ml of Luria broth supplemented with 100 μg/ml
ampicillin. 1 ml of the overnight culture was used to inoculate a 500-
ml culture. The larger culture was incubated approximately 3 h until
the OD600 reached approximately 0.6, at which point it was induced
with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 12 h at
30 °C. The bacteria were pelleted, washed once with STE buffer
(100 mM NaCl, 10 mM Tris, and 1 mM EDTA, pH 7.5), resuspended in
3 ml NETN buffer (0.5% NP-40, 100 mMNaCl, 20 mM Tris, 1 mM EDTA,
pH 8.0) supplemented with protease inhibitors, and incubated on ice
for 15 min. 150 μl of 1 M dithiothreitol (DTT) and 1.8 ml of a 10%
solution of Sarkosyl in STE buffer was added, and the suspension was
sonicated (for 3 min on ice) to solubilize the proteins. The lysate was
centrifuged (12,000 ×g, 10 min, 4 °C) to separate the unsolubilized
fraction. The clear supernatant was transferred to a fresh tube, to
which 3 ml of 10% Triton X-100 in STE buffer and 200 μl of glutathione
Sepharose beads were added. The tube was rotated overnight at 4 °C,
after which the puriﬁed protein bound to glutathionewas collected by
centrifugation (2 min, 600 ×g, 4 °C) and washed ﬁve times with NETN
buffer supplemented with protease inhibitors. Level of puriﬁcation
was judged by SDS-PAGE and puriﬁed proteins were stored at 4 °C.
Immunoprecipitation and western blotting
Transfected cells were harvested, washed in ice-cold PBS, and lysed
in 0.5 ml ice-cold radioimmunoprecipitation assay (RIPA) buffer [0.5%
NP-40, 10 mM Tris pH 7.5, 2 mM EDTA, 150 mM NaCl supplemented
with protease inhibitors—1 mM phenylmethylsulphonyl ﬂuoride
(PMSF), 1 μg/ml aprotinin, 1 μg/ml pepstatin and 1 μg/ml leupeptin].
Cellular debris was removed by centrifugation (21,000 ×g, 10 min,
4 °C), and the supernatant was transferred to a fresh tube.
Approximately 5% of the lysate was saved as an input control. Lysates
were then precleared with normal mouse serum and then rotated
with 30 μl of a 1:1 mixture of protein A- and protein G-conjugated
Sepharose beads for 1 h, at 4 °C. Beads were spun out, and the
supernatant was transferred to a fresh microcentrifuge tube andapproximately 5% of the lysatewas saved for input control. The protein
of interest was captured by rotating overnight the remaining lysate
with 1 μg of speciﬁc antibody at 4 °C. Complexes were precipitated
with 30 μl of 1:1 mixture of protein A- and protein G-Sepharose beads.
The samples were washed three times with ice-cold RIPA buffer,
fractionated by SDS-PAGE, and transferred to a 0.45 μm nitrocellulose
membrane for western blotting (WB). The membranes were probed
with the appropriate antibodies followed by incubation with appro-
priate infrared-tagged secondary antibodies for 1 h at room
temperature (RT) and viewed on an Odyssey imager (LiCor Inc.,
Lincoln, NE).
Immunoﬂuorescence
BJAB, LCL1 and LCL2 cells were dried onto slides and ﬁxed using a
1:1 mixture of acetone and methanol. After ﬁxation cells were
extensively washed in PBS and incubated in blocking buffer [PBS
supplemented with 0.1% Triton X 100, 0.2% ﬁsh skin gelatin (Sigma)]
at room temperature for 30 min. Endogenous expression of p53 was
detected using mouse monoclonal antibody DO-1 (1:200 dilution),
and EBNA3C was detected using EBNA3C-reactive human serum
(1:150 dilution). Primary antibodies were diluted in blocking buffer
and incubated with ﬁxed cells for 1 h at RT. Cover slips were washed
three times (5 min each) with PBS and incubated with appropriate
secondary antibody (1:2000) for 1 h at RT followed by three times
washes (5 min each) with PBS. The last wash contained 4′, 6′-
diamidino-2-phenylindole (DAPI; Promega Inc., Madison, WI) for
nuclear staining. Goat anti-human antibody Alexa Fluor 488 and goat
anti-mouse antibody Alexa Fluor 594 were purchased fromMolecular
Probes Inc. (Carlsbad, CA). Cover slips were then washed in PBS and
mounted using Prolong anti-fade (Molecular Probes Inc, Carlsbad,
CA). Fluorescence was viewed by confocal microscopy and analyzed
with Fluoview 300 software from Olympus Inc. (Melville, NY).
Reporter assays
Reporter assay was essentially performed as described previously
(Bajaj et al., 2008) with few modiﬁcations. Brieﬂy, either 0.4×106
SAOS-2 or 1.0×106 BJAB cells were co-transfected with 0.25 μg of the
promoter construct containing p53 responsive element and 0.5 μg
pA3M-p53 and increasing amount of pA3F-EBNA3C constructs (0,
0.25, 0.5, 1.0 μg) expressing wild-type p53 and EBNA3C respectively
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The differences
in the amounts of total DNA were equalized with vector control to
keep the total amount of transfected DNA constant. At 24 h post-
transfection, cells were collected and washed with ice-cold PBS, and
lysed in 100 μl of reporter lysis buffer (Promega Inc., Madison, WI). A
40 μl aliquot of the lysatewas transferred to a 96-well plate. Luciferase
activity was measured using an LMaxII384 luminometer (Molecular
Devices, Sunnyvale, CA) by automatically injecting 25 μl of luciferase
substrate into each well and integrating the luminescence for 20 s
postinjection. The results represent experiments performed in
duplicate.
Electrophoretic mobility shift assay (EMSA)
EMSA was essentially performed as described previously (Lan et
al., 2006). Equivalent amount of nuclear extract was used in each
EMSA reaction. The probe containing the p53 responsive element (5′-
GTCAGGAACATGTCCCAACATGTTGAGCTC-3′) of the p21 promoter
(Fujioka et al., 2004) was labeled by Klenow ﬁll-in reaction with
α-32P dCTP and puriﬁed with NucTrap probe puriﬁcation columns
(Stratagene, Inc., La Jolla, CA). Reactionmixture consisted of 0.02 pmol
of labeled probe and 5 μg of nuclear extract protein in a buffer
consisting of 20 mM HEPES (pH 7.5), 0.01% NP-40, 40 mM KCl, 100 μg
BSA, 2.5 mM MgCl2, 20 mM DTT, 5% glycerol. Poly(dI/dC) (Sigma-
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and the ﬁnal volume (50 μl) of the reactionmixture was adjusted with
appropriate amount of double-distilled H2O. Following incubation at
25 °C for 25 min, the DNA–protein complexes were resolved by
nondenaturing 4% polyacrylamide gel electrophoresis. The gel was run
in 0.5×TBE buffer (45 mM Tris-borate, 1 mM EDTA, pH 8.0) at a
constant voltage of 120 V for 4 h at 4 °C. Following electrophoresis, the
gel was transferred toWhatman paper and dried for 1 h at 80 °C. Dried
gels were exposed to a phosphorimager screen for 12 h (Amersham
Biosciences, Inc., Piscataway, NJ) and scanned by a PhosphorImager
(Molecular Dynamics, Piscataway, NJ). For supershift experiment,
monoclonal antibody against p53 was added (DO-1) after an initial
30-min incubation of probe with nuclear extract and incubated for 1 h
at 4 °C.
Apoptosis assay
SAOS-2 cells were co-transfected with constructs expressing myc-
tagged p53 and ﬂag-tagged EBNA3C (as indicated in the text and
ﬁgure) plus GFP expressing plasmid (pEGFP-C1; BD Biosciences
Clontech) for checking transfection efﬁciency. At 48 h post-transfec-
tion, ﬂoating and attached cells were collected, washed in ice-cold
PBS. Cells were then resuspended in PBS and ﬁxed in 90% cold ethanol.
Following incubation cells were stained with PBS containing 40 μg/ml
of propidium iodide (PI), 200 μg/ml of RNase A (Sigma) and 0.05%
Triton X-100 for 1 h at RT in dark. Stained cells were analyzed on
FACScan (Becton-Dickinson). Total 20,000 events were analyzed for
each sample. Data was analyzed using the ModFIT model program
(Verity software House).
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